Short Interest in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Drops By 72.6%

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 15,622 shares, a decrease of 72.6% from the July 15th total of 57,108 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily volume of 28,692 shares, the short-interest ratio is presently 0.5 days.

Institutional Trading of iShares Genomics Immunology and Healthcare ETF

A hedge fund recently raised its stake in iShares Genomics Immunology and Healthcare ETF stock. Ameriprise Financial Inc. boosted its position in shares of iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) by 8.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 71,473 shares of the company’s stock after acquiring an additional 5,540 shares during the quarter. Ameriprise Financial Inc. owned 1.42% of iShares Genomics Immunology and Healthcare ETF worth $1,688,000 at the end of the most recent reporting period.

iShares Genomics Immunology and Healthcare ETF Trading Down 0.0%

NYSEARCA:IDNA traded down $0.01 during trading hours on Friday, reaching $35.23. The company had a trading volume of 48,317 shares, compared to its average volume of 43,659. iShares Genomics Immunology and Healthcare ETF has a 52 week low of $22.12 and a 52 week high of $35.51. The firm has a market cap of $207.86 million, a price-to-earnings ratio of 14.76 and a beta of 0.93. The firm’s 50 day moving average price is $32.61 and its 200-day moving average price is $30.59.

iShares Genomics Immunology and Healthcare ETF Company Profile

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.